Company Overview and News
Standard & Poor's believes risks remain high around the supply of ethically sourced cobalt from the world’s largest producer, Democratic Republic of Congo (DRC).
BPL CFE CMULF BPLNF
Broken Hill Prospecting’s joint Thackaringa cobalt project with Cobalt Blue has received strong results from its pre-feasibility study (PFS), indicating the project to be low-cost, high-purity, globally significant source of cobalt sulphate.
Broken Hill Prospecting Ltd (ASX:BPL) has received positive pre-feasibility study results and a maiden ore reserve estimate for the Thackaringa Cobalt Project near Broken Hill in New South Wales.
Cobalt Blue Holdings Ltd (ASX:COB) has received positive results from a pre-feasibility study (PFS) into the Thackaringa Cobalt Project near Broken Hill that justify proceeding towards commercial development.
Broken Hill Prospecting Ltd (ASX:BPL) has been granted a trading halt pending the release of a pre-feasibility study on the Thackaringa Cobalt Project of joint venture partner Cobalt Blue Holdings Ltd (ASX:COB).
Cobalt Blue Holdings Ltd (ASX:COB) will this week release its first ore reserve estimate and finalised pre-feasibility study (PFS) for the Thackaringa Cobalt Project at Broken Hill.
VBS BPL BPLNF AEI
Indian state-owned firms mandated to acquire overseas lithium and cobalt assets - A rough deadline of March 2019.
SIE PIO CLA PANRF CCZ PAN HAV MCR KBGCF CTM AXE IGO VIC BAR AOU HIG PCRCF PLM.RT TAKRF SNNAF FQM MCRZF BXTMF MLX PSDNF POM AYR CDU RGARF CHK MCRZY FTMDF KAT RER CSSQF GMRSF CZN PGM GBLEF NZRIF AZS DLE HBNRF MEI PIONF BPLNF CZI AMSLF HMI POS AUZ RNX GME FQVLF AQR PTNUF PCRFY FT HNLMF ORR CDNMD CDNMF IIDDY AEOMF USCFF KATFF BBBMF MLXEF OZMLF PLM CNJ AZRMF TSLA HLPCF BPL BHP OZL ARV
Cobalt Blue Holdings Ltd (ASX:COB) has a change in the board, with Trangie Johnston resigning as a non-executive director to focus on his managing director position at Broken Hill Prospecting Ltd (ASX:BPL).
Six cobalt junior developers can each produce ~5,000 tonnes pa of cobalt by 2021/22. These companies each have the potential to be worth ~AUD 3b if cobalt prices remain strong.
CLA CCZ HAV GLCNF ECSIF CZI AMSLF BPLNF POS HIG AUZ RNX RNKLF GME AQR FT PSDNF AYR AEOMF KATFF RNX.WT FTMDF KAT CNJ BPL HLPCF CSSQF
Broken Hill Prospecting Ltd (ASX:BPL) has been granted four new exploration licences which firmly establishes its position as the largest mineral sands tenement holder in the Murray Basin.
Castillo Copper Ltd (ASX:CCZ) has identified six cobalt prospects near Broken Hill with the same geological sequence as the nearby Thackaringa deposit of Cobalt Blue Holdings Ltd (ASX:COB).
CCZ AXE BPL BPLNF
Cobalt miner news - South Korea's LG Chem to set up battery material JVs with China's Zhejiang Huayou Cobalt.
SIE PIO PANRF CCZ PAN HAV MCR KBGCF FCX IGO VIC BAR AOU HIG PCRCF PLM.RT TAKRF SNNAF FQM MCRZF BXTMF MLX PSDNF POM AYR SHERF CDU RGARF CHK MCRZY FTMDF KAT RER CSSQF GMRSF CZN PGM GBLEF NZRIF AZS DLE HBNRF MEI PIONF CZI AMSLF BPLNF HMI POS AUZ RNX GME FQVLF AQR PTNUF FT HNLMF ORR CDNMD CDNMF IIDDY AEOMF USCFF KATFF MLXEF OZMLF PLM CNJ AZRMF HLPCF BPL BHP OZL ARV
Cobalt Blue Holdings Ltd (ASX:COB) has retained its 51% beneficial ownership in the Thackaringa Cobalt Project Joint Venture after completing stage I earn-in requirements.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to ASX:BPL / BROKEN HILL PROSPECTING LIMITED on message board site Silicon Investor.
|Broadband over power lines-BPL : 1) TELKONET -TKO u0026 2) AMBIE||Bank Plus (BPLS)|
|Bio Plexus, Inc. BPLX||Barrington Petroleum...BPL:tse|